Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
RI

NASDAQ · RIGL

Rigel Pharmaceuticals, Inc.

Healthcare · Biotechnology

$51.31

Down-$0.14 (-0.27%)

Updated Oct 31, 2026, 5:37 PM

SID Score

7.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
751.68M
P/E ratio
6.71
Dividend yield
0.00%
52-week range
$24.95 – $52.24
Volume
174.41K
Avg. volume
631.51K

Price performance · RIGL

RIGL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

RIGL closed at $51.31 after 21 trading sessions, up 8.82% for the selected period.

Last close
$51.31
Period change
+8.82%
Period low
$45.97
Period high
$51.45
Daily close
View OHLC price history
RIGL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$51.80$52.605$50.67$51.31174.41K
Oct 29, 2026$51.17$51.60$50.2411$51.45159.56K
Oct 28, 2026$50.26$51.36$50.055$50.74226.33K
Oct 27, 2026$50.09$50.70$49.5401$50.55133.1K
Oct 26, 2026$48.63$50.00$48.3201$49.91196.56K
Oct 23, 2026$48.48$48.48$47.47$48.13119.26K
Oct 22, 2026$48.97$49.935$48.55$48.86152.64K
Oct 21, 2026$47.64$49.01$47.64$48.88195.89K
Oct 20, 2026$46.73$48.16$46.73$48.11366.26K
Oct 19, 2026$46.39$47.385$45.48$46.72318.41K
Oct 16, 2026$47.58$47.58$45.68$45.97141.43K
Oct 15, 2026$47.01$48.515$47.01$47.25167.85K
Oct 14, 2026$46.82$47.99$46.37$46.82160.1K
Oct 13, 2026$48.70$48.87$47.04$47.14134K
Oct 12, 2026$49.22$49.89$48.535$48.81162.53K
Oct 9, 2026$48.60$50.4892$48.60$49.08279.36K
Oct 8, 2026$47.33$48.89$46.56$48.72216.85K
Oct 7, 2026$45.64$48.15$45.22$47.99232.58K
Oct 6, 2026$48.18$48.18$45.93$46.11202.6K
Oct 5, 2026$47.02$48.8346$46.93$47.79391.63K
Oct 2, 2026$47.66$48.00$46.45$47.15185.67K

Latest RIGL news

The latest Smart Investors Daily articles mentioning RIGL.

Stock researchCompany · Overview

RIGL research

Overview

Company profile and research snapshot.

Company profile

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$40.00
Implied upside
—
Analysts
12
RIGL recent ratings
DateFirmRatingTarget
Oct 19, 2026HC Wainwright & Co.Buy—
Aug 17, 2026Piper SandlerNeutral—
Aug 14, 2026HC Wainwright & Co.Buy—
Jun 2, 2026HC Wainwright & Co.Buy—
May 27, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Rigel Pharmaceuticals Shares Rose Even As Profit Fell

If you only saw Rigel Pharmaceuticals’ latest quarterly results, with revenue and net income both lower than a year earlier and net margin compressed from 58.6% to 22.0%, you might assume shareholders had a rough ride. Investors who held Rigel Pharmaceuticals over the past year are up 66.2%, including dividends. If you were weighing an investment on 22 October 2025, what did the mix of pipeline promise and earnings quality really signal about taking that risk? Rigel Pharmaceuticals is not the...

Yahoo · Oct 19, 2026

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced analysis of the pooled efficacy and safety data from two clinical trials of GAVRETO® (pralsetinib), ARROW (NCT03037385) and TAPISTRY (NCT04589845), in patients with rearranged during transfection (RET) fusion-positive solid tumors will be presented in a rapid oral session at the European Society For Medical Oncology (ESMO) Congress 2026 on Sunday, Octo

Yahoo · Oct 6, 2026

Knight Therapeutics Announces Launch of TAVALISSE® in Brazil

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1 “With today's launch, TAVALISSE® is now available to adults in Brazil living with chronic ITP who have not responded adequately to

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By